Literature DB >> 15970476

Uremic cardiomyopathy: role of circulating digitalis like substances.

Behram Mohmand1, Deepak K Malhotra, Joseph I Shapiro.   

Abstract

Patients with chronic renal failure develop a cardiomyopathy characterized by marked diastolic dysfunction and left ventricular hypertrophy. Interestingly, they also have substantial increases in the circulating concentrations of digitalis like substances. Digitalis like substances produce reactive oxygen species as part of the signal cascade induced by binding to the sodium pump and patients, and this signal cascade appears to induce hypertrophy of cardiac myocytes grown in culture. Also, patients with chronic renal failure develop an oxidant stress state without a known mechanism. From these data, we propose that it is these digitalis like substances which cause cardiomyopathy of renal failure as well as the systemic oxidant stress state.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15970476     DOI: 10.2741/1679

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  10 in total

Review 1.  Targeting Na/K-ATPase Signaling: A New Approach to Control Oxidative Stress.

Authors:  Jiang Liu; Megan N Lilly; Joseph I Shapiro
Journal:  Curr Pharm Des       Date:  2018       Impact factor: 3.116

Review 2.  Endogenous digitalis: pathophysiologic roles and therapeutic applications.

Authors:  Alexei Y Bagrov; Joseph I Shapiro
Journal:  Nat Clin Pract Nephrol       Date:  2008-06-10

Review 3.  Endogenous cardiotonic steroids: physiology, pharmacology, and novel therapeutic targets.

Authors:  Alexei Y Bagrov; Joseph I Shapiro; Olga V Fedorova
Journal:  Pharmacol Rev       Date:  2009-03       Impact factor: 25.468

Review 4.  Endogenous cardiotonic steroids in kidney failure: a review and an hypothesis.

Authors:  John M Hamlyn; Paolo Manunta
Journal:  Adv Chronic Kidney Dis       Date:  2015-05       Impact factor: 3.620

Review 5.  Sodium potassium adenosine triphosphatase (Na/K-ATPase) as a therapeutic target for uremic cardiomyopathy.

Authors:  Xiaoliang Wang; Jiang Liu; Christopher A Drummond; Joseph I Shapiro
Journal:  Expert Opin Ther Targets       Date:  2017-04-03       Impact factor: 6.902

6.  A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy.

Authors:  Xiaoliang Wang; Muhammad A Chaudhry; Ying Nie; Zijian Xie; Joseph I Shapiro; Jiang Liu
Journal:  J Vis Exp       Date:  2017-11-07       Impact factor: 1.355

7.  Gender differences in the development of uremic cardiomyopathy following partial nephrectomy: Role of progesterone.

Authors:  Christopher A Drummond; George Buddny; Steven T Haller; Jiang Liu; Yanling Yan; Zijian Xie; Deepak Malhotra; Joseph I Shapiro; Jiang Tian
Journal:  J Hypertens (Los Angel)       Date:  2013-01-31

8.  Attenuation of Na/K-ATPase Mediated Oxidant Amplification with pNaKtide Ameliorates Experimental Uremic Cardiomyopathy.

Authors:  Jiang Liu; Jiang Tian; Muhammad Chaudhry; Kyle Maxwell; Yanling Yan; Xiaoliang Wang; Preeya T Shah; Asad A Khawaja; Rebecca Martin; Tylor J Robinette; Adee El-Hamdani; Michael W Dodrill; Komal Sodhi; Christopher A Drummond; Steven T Haller; David J Kennedy; Nader G Abraham; Zijian Xie; Joseph I Shapiro
Journal:  Sci Rep       Date:  2016-10-04       Impact factor: 4.379

Review 9.  The Role of Na/K-ATPase Signaling in Oxidative Stress Related to Aging: Implications in Obesity and Cardiovascular Disease.

Authors:  David E Bartlett; Richard B Miller; Scott Thiesfeldt; Hari Vishal Lakhani; Joseph I Shapiro; Komal Sodhi
Journal:  Int J Mol Sci       Date:  2018-07-23       Impact factor: 5.923

10.  Cardiac Oxidative Signaling and Physiological Hypertrophy in the Na/K-ATPase α1s/sα2s/s Mouse Model of High Affinity for Cardiotonic Steroids.

Authors:  Pauline V Marck; Marco T Pessoa; Yunhui Xu; Laura C Kutz; Dominic M Collins; Yanling Yan; Cierra King; Xiaoliang Wang; Qiming Duan; Liquan Cai; Jeffrey X Xie; Jerry B Lingrel; Zijian Xie; Jiang Tian; Sandrine V Pierre
Journal:  Int J Mol Sci       Date:  2021-03-27       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.